-+ 0.00%
-+ 0.00%
-+ 0.00%

ABVC BioPharma Determined That It Has A Material Weakness In Its Internal Controls Over Financial Reporting; Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements

Benzinga·04/15/2025 20:43:26
Listen to the news

- SEC Filing